Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease – Business Wire

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease  Business Wire